SNIBE(SZ:300832) Ping An Securities·2025-11-03 03:24Investment Rating - The report maintains a "Recommended" investment rating for the company [1][8]. Core Views - The company's Q3 performance shows gradual improvement, with domestic market recovery and enhanced overseas profitability [4][5]. - Domestic revenue for the first three quarters of 2025 reached 1.955 billion yuan, a year-on-year decrease of 11%, primarily due to centralized procurement and the unbundling of testing packages [4]. - The overseas market demonstrated strong performance, with revenue of 1.467 billion yuan, a year-on-year increase of 21%, driven by a 37% increase in reagent sales [5]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved revenue of 3.428 billion yuan, a year-on-year increase of 0.39%, and a net profit of 1.205 billion yuan, a year-on-year decrease of 12.92% [3]. - Q3 revenue was 1.243 billion yuan, up 3.28% year-on-year, with a net profit of 434 million yuan, down 9.72% year-on-year [3]. Domestic Market Insights - The domestic market is gradually bottoming out, with significant results from the large customer strategy [4]. - The company installed 1,144 units of luminous equipment in the domestic market, with large machines accounting for 78% of the total, indicating an improved installation structure compared to the same period in 2024 [4]. Overseas Market Insights - The overseas business is performing well, with reagent sales significantly increasing and gross profit margins improving to 69.49%, surpassing domestic levels [5]. - The company sold 2,631 units of luminous instruments overseas, with mid-to-large size instruments making up 76% of sales [5]. Financial Projections - Revenue projections for 2025-2027 are adjusted to 2.25 yuan, 2.75 yuan, and 3.36 yuan for EPS, reflecting a downward revision due to policy pressures [8]. - The company continues to focus on the in-vitro diagnostic field, expanding both domestic and overseas markets, which is expected to drive growth [8]. Key Financial Ratios - The company’s gross margin for Q3 was 69.24%, slightly improved from the first half of the year, primarily due to enhanced overseas margins [8]. - The sales expense ratio was 16.86%, and the R&D expense ratio was 10.86%, indicating ongoing investment in academic promotion and product development [8].